CN103071020A - Externally applied ointment for treating child trachitis-bronchitis and pneumonia, and preparation method thereof - Google Patents
Externally applied ointment for treating child trachitis-bronchitis and pneumonia, and preparation method thereof Download PDFInfo
- Publication number
- CN103071020A CN103071020A CN2012105843531A CN201210584353A CN103071020A CN 103071020 A CN103071020 A CN 103071020A CN 2012105843531 A CN2012105843531 A CN 2012105843531A CN 201210584353 A CN201210584353 A CN 201210584353A CN 103071020 A CN103071020 A CN 103071020A
- Authority
- CN
- China
- Prior art keywords
- bronchitis
- pneumonia
- external application
- children
- tracheal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to an externally applied ointment for treating child trachitis-bronchitis and pneumonia, and a preparation method thereof. The externally applied ointment is prepared from the following traditional Chinese medicinal raw materials: pseudo-ginseng, paris polyphylla, polygonum cuspidatum, houttuynia cordata and liquorice; and auxiliary materials comprises glycerin monostearate, albolene, stearic acid, sodium laurylsulfate, glycerol, azone and nipagin ethyl ester oil. The externally applied ointment is prepared by performing ethanol extraction, water extraction, hot melting, heating and the like on the raw materials according to different characteristics of the raw materials and different parts by weight. The invention also particularly discloses the components of the externally applied ointment and the proportion of the components. The product is unique in formula and preparation and has obvious curative effect of treating child trachitis-bronchitis and pneumonia.
Description
Technical field
The invention belongs to medical technical field, specifically be used for external application ointment formulation and the processing technology thereof of children with tracheal-bronchitis, pneumonia treatment.
Background technology
World Health Organization (WHO) thinks that the department of pediatrics five large causes of death are acute respiratory infection ARI, diarrhoea, measles, malaria and malnutrition.And ARI is that the five large causes of death are the first, and wherein pneumonia is one of four large common diseases that threaten the Chinese children health and lives, and its morbidity number, the number average of dying of illness occupy first of the pediatric disease.Developing country infantile pneumonia pathogenetic bacteria mostly is virus, therefore in lower respiratory infection, use antibiotic maximum be pneumonia.
For tracheitis and bronchitis and pneumonia, pneumonia especially, for many years always take the intravenous drip antibiotic and or antiviral drugs as main comprehensive treatment.Only have minority to add and use treatment by Chinese herbs, antibiotic being widely used, especially irrational use, abuse constantly increase Resistant strain, and the whole mankind's life and health in serious threat.The antibiotic of newly development upgrading is expensive, and the financial burden that has increased infants ' parents is also corresponding to have restricted national economic development, and the increase of its side effect also exists potential danger.Venous transfusion itself just exists unsafe factor, and the whole nation constantly increases because of medical accident and the death toll that venous transfusion occurs, and infant also feels more painful because fearing venipuncture, and staying in the ward to look after the patient night and day, delaying work of the head of a family also makes it can't bear the heavy load.
In addition, disclosed application for the infantile bronchitis pneumonia is paste among the patent CN1299651A, clinical trial shows and has following shortcoming: 1, when making owing to do not pass through the extraction of the effective ingredient of medicine, actually be black plaster, skin can not very fast absorption behind its coating, and the incidence rate of local skin erythra has reached more than 47% behind the coating; 2, since this application directly contact skin and apply after need to continue the long period, have obvious discomfort; 3, to the healing fall flat of infantile bronchitis pneumonia, cure rate is low.
Summary of the invention
The present invention is directed to the problems referred to above, researched and developed a kind of external application ointment and method for making thereof for children with tracheal-bronchitis, pneumonia treatment, obviously shortened the natural law of intravenous drip antibiotic or antiviral drugs, effectively alleviated the misery of infant and to refractory pneumonia better efficacy such as organizing pneumonias with the external application ointment formulation therapy of these research and development, the treatment of pneumonia acute stage has also been had obvious curative effects.
Technical scheme of the present invention is: a kind of processing technology of the external application ointment for children with tracheal-bronchitis, pneumonia, and key is: this processing technology may further comprise the steps:
(1) will effectively treat component gets the raw materials ready according to following ratio of weight and number:
Radix Notoginseng 55-65 part,
Rhizoma Paridis 25-35 part,
Rhizoma Polygoni Cuspidati 25-35 part,
Herba Houttuyniae 40-50 part,
Radix Glycyrrhizae 10-20 part;
(2) above-mentioned each component is pulverized respectively, is sieved:
(3) Radix Notoginseng after will pulverizing, sieving, Rhizoma Paridis soak with ethanol, separation soaking liquid, concentrated that the liquid alcohol extract is for subsequent use;
(4) Rhizoma Polygoni Cuspidati after will pulverizing, sieving, Herba Houttuyniae, Radix Glycyrrhizae water decoct, and the isolated by filtration medicinal liquid, concentrated to obtain water extract stand-by;
(5) effective technique component is got the raw materials ready according to following ratio of weight and number:
Glyceryl monostearate 65-75 part,
White vaseline 80-90 part,
Stearic acid 110-115 part,
Sodium laurylsulfate 8-12 part,
Glycerol 80-90 part,
The 1-3% of the above weight summation of azone,
The 1-3 ‰ of the above weight summation of ethyl hydroxybenzoate,
(6) with above-mentioned vaseline, stearic acid, glyceryl monostearate, ethyl hydroxybenzoate mixing hot melt, and stir to oil phase, for subsequent use;
(7) sodium laurylsulfate, glycerol, azone are mixed, and add in the step (3) in the alcohol extract, with step (4) in water extract remix, be heated to water, for subsequent use;
(8) oil phase that step (6) is obtained is added to aqueous phase, stirs, and can make external application ointment after being cooled to room temperature;
(9) pack, dispatch from the factory.
Radix Notoginseng in the step (3), Rhizoma Paridis soak with ethanol are carried out in two steps, soak 1-3 hour for the first time, isolate raw material adding ethanol and carry out the immersion second time, soak 12-24 hour, after the separation, concentrate alcohol extract for subsequent use.
Used concentration of alcohol is 60-70%.
Alcohol extract is concentrated in step (3), and being concentrated into proportion is that 1.1-1.3 is for subsequent use.
Rhizoma Polygoni Cuspidati after step will be pulverized in (4), sieve, Herba Houttuyniae, Radix Glycyrrhizae water decoct, the isolated by filtration medicinal liquid carries out in two steps, the first step decocts with water 1-1.5 hour, isolate medicinal residues and decoct with water again 40-60 minute, the filtering medicinal residues, concentrated after twice aqueous extract mixes.
Concentrate after said aqueous extract mixes and finish in concentration tank, the extracting solution proportion after concentrating reaches 1.1-1.3.
Pulverizing described in the step (2), the operation of sieving are that Radix Notoginseng, Rhizoma Paridis, Rhizoma Polygoni Cuspidati, Herba Houttuyniae, Radix Glycyrrhizae powder are broken to the 18-22 order.
A kind of external application ointment for children with tracheal-bronchitis, pneumonia treatment,, comprise in the components by weight percent of the raw material of Chinese medicine in this external application ointment than selecting materials, obtaining liquid active ingredients, mix mutually the medicine of formation with the oil phase adjuvant via extraction process according to prescription Chinese herbal medicine components by weight percent:
Radix Notoginseng 55-65 part,
Rhizoma Paridis 25-35 part,
Rhizoma Polygoni Cuspidati 25-35 part,
Herba Houttuyniae 40-50 part,
Radix Glycyrrhizae 10-20 part.
Comprise in the components by weight percent of the oil phase adjuvant in this external application ointment:
Glyceryl monostearate 65-75 part,
White vaseline 80-90 part,
Stearic acid 110-115 part,
Sodium laurylsulfate 8-12 part,
Glycerol 80-90 part,
The 1-3% of the above weight summation of azone,
The 1-3 ‰ of the above weight summation of ethyl hydroxybenzoate.
The invention has the beneficial effects as follows: this external application ointment is extracted, is made behind the efficient concentration by effective ingredient, obviously reduce behind the coating and with the gargalesthesia infant, only be＜1%, and other traditional pneumonia plasters when making owing to do not pass through the extraction of the effective ingredient of medicine, actually be black plaster, the incidence rate of local skin erythra has reached more than 47% behind its coating.This shows, be far superior to other pneumonia plasters at this external application ointment formulation aspect the minimizing side effect.Moreover this external application ointment is dosage form, directly is applied in use on the skin, can be absorbed by the skin very soon, is accepted by the patient than traditional plaster is easier, deeply is subjected to liking of infant and the head of a family.
Children's's body surface area is larger, and the chest and back subcutaneous fat is less, and contained three kinds of medicines that function of promoting blood circulation to disperse blood clots arranged all have short skin Absorption in various degree in this external application ointment, is share azone again and can reach promote medicine to absorb fast and the purpose for the treatment of fully.Have 15 acupuncture points in the ointment coating scope of this therapy: 2 in feishu cave, 2 of GAOGUANG acupoint, 1 of Body Pillar acupoint, HUATUOJIAJI acupoint breast 3-----breast 12 totally 10, effective to the treatment of pneumonia, tracheitis and bronchitis.Skin to the absorption of medicine in addition medicine be to kill two birds with one stone to the effect at these 15 acupuncture points, amplified therapeutical effect.
Monarch drug is the medicine that plays a major role in prescription, and ministerial drug is to assist monarch drug to reach the medicine of Main Function.So except monarch drug, ministerial drug has also played the important function that is only second to monarch drug in prescription.By the research of patent CN1299651A and clinical trial are found, the ministerial drug that forms in the component of disclosed application does not play good effect, causes the therapeutic effect of application low.We have added another flavor ministerial drug-Rhizoma Polygoni Cuspidati by long term test in the external application ointment formulation for the treatment of children with tracheal-bronchitis, pneumonia, this helper who increases is a very strong assistant.1), the function of blood circulation promoting and blood stasis dispelling, relieving stagnation and freeing network vessels, anti-erythrocyte and antiplatelet aggregation arranged the adding of Rhizoma Polygoni Cuspidati has played three aspects::, assist and strengthen the monarch drug Radix Notoginseng improve the microcirculatory effect of lung, make the lung microcirculation unobstructed, blood plasma oozes out minimizing, so just alleviated hypoxic-ischemic, alleviate pulmonary epithelial cells swelling and necrosis, alveolar structure is early recovered.On the other hand, the microcirculatory improvement of lung also makes the macrophage phagocytic digestion power in the lung tissue strengthen, also can secrete a large amount of interferon and make natural killer cell--the NK cytoactive strengthens with the deactivation cause of disease, remove as early as possible cause of disease, degeneration necrosis tissue and exudate become pneumonopathy and organize early reparation.In addition, complementing each other of Rhizoma Polygoni Cuspidati and monarch drug Radix Notoginseng, ministerial drug Rhizoma Paridis also can be improved the immunity of organisms of infant except making the improvement of lung microcirculation, promotes the early recovery of pneumonia.2) have antibiotic, antiviral effect, cooperate with Herba Houttuyniae, Radix Glycyrrhizae common disease-resistant former so that antibiotic, antivirus action is used more strong in the treatment of infectious respiratory tract disease.3) Rhizoma Polygoni Cuspidati has antitussive, antiasthmatic effect, with the cough with asthma of Rhizoma Paridis, Radix Glycyrrhizae co-therapy pneumonia, tracheitis so that antitussive, antiasthmatic effect real for the treatment of respiratory system cough with asthma be favourable.In a word, the adding of Rhizoma Polygoni Cuspidati has shown blood circulation promoting and blood stasis dispelling, has improved the lung microcirculation, larger superiority aspect antibiotic, the antiviral, antitussive and antiasthmatic in treatment tracheitis and bronchitis, pneumonia.
Ministerial drug is Rhizoma Paridis, Rhizoma Polygoni Cuspidati in the present invention's prescription, and the two all has blood circulation promoting and blood stasis dispelling, and antiplatelet aggregation assists Radix Notoginseng to improve the microcirculatory effect of lung.In addition, Rhizoma Paridis still has heat-clearing and toxic substances removing, relieving cough and asthma, calmness and antibiosis and antiviral functions; That Rhizoma Polygoni Cuspidati still has is antibiotic, antiviral, antitussive and antiasthmatic function.Adjuvant drug is Herba Houttuyniae, has heat-clearing and toxic substances removing, and the heat of reducing phlegm disappear lung abscess and obvious antibiotic and antivirus action can strengthen the leukocytes phagocytic ability and improve the function of immunity of organisms.Be widely used evident in efficacy to upper and lower respiratory tract infection.Making medicine is Radix Glycyrrhizae, and Chinese materia medica is decided to be Qi-tonifying drug with it, and the effect of the invigorating the heart and spleen deficiency of vital energy is arranged, and the effect of adrenocortical hormone sample is still arranged, and antiinflammatory, antiallergic, antiviral, protection Detoxication are arranged, the coordinating the actions of various ingredients in a prescription that the traditional Chinese medical science is commonly used.It both can alleviate the inflammatory reaction of pulmonary, alleviated the permeability of the local wall of micrangium of lung, reduced blood plasma and oozed out, and alleviated the generation of the erythra that the local skin stimulation is occurred.Azone is effectively short cutaneous permeable agent, can promote the effective ingredient of medicine to penetrate into fast in the interior lung tissue of body.Electromagnetic irradiation, make the telangiectasis in the skin accelerate the quick absorption of medicine, drug for invigorating blood circulation and eliminating stasis itself also has this effect, use anteroposterior diameter electromagnetic wave irradiation or pad towel to seal the absorption that hot skin rubefaction more is conducive to skin at this external application ointment formulation, also saved simultaneously gauze, use the convenient welcome that more is subjected to infant and the head of a family thereof, more be better than traditional ointment plaster.
The specific embodiment
When concrete the use, take by weighing raw material (gram) by following proportioning:
Embodiment 1, Radix Notoginseng 62, Rhizoma Paridis 33, Rhizoma Polygoni Cuspidati 33, Herba Houttuyniae 47, Radix Glycyrrhizae 18, and effective technique adjuvant: glyceryl monostearate 72, white vaseline 87, stearic acid 114, sodium laurylsulfate 11, glycerol 87, azone, ethyl hydroxybenzoate, wherein, azone be above-mentioned effective technique adjuvant weight summation 1.5%, ethyl hydroxybenzoate is 1 ‰ of above-mentioned effective technique adjuvant weight summation.
Embodiment 2, Radix Notoginseng 55, Rhizoma Paridis 25, Rhizoma Polygoni Cuspidati 25, Herba Houttuyniae 40, Radix Glycyrrhizae 10, and effective technique adjuvant: glyceryl monostearate 65, white vaseline 80, stearic acid 110, sodium laurylsulfate 8, glycerol 80, azone, ethyl hydroxybenzoate, wherein, azone be above-mentioned effective technique adjuvant weight summation 1%, ethyl hydroxybenzoate is 1.5 ‰ of above-mentioned effective technique adjuvant weight summation.
Embodiment 3, Radix Notoginseng 60, Rhizoma Paridis 30, Rhizoma Polygoni Cuspidati 30, Herba Houttuyniae 45, Radix Glycyrrhizae 15, and effective technique adjuvant: glyceryl monostearate 70, white vaseline 85, stearic acid 112, sodium laurylsulfate 10, glycerol 85, azone, ethyl hydroxybenzoate, wherein, azone be above-mentioned effective technique adjuvant weight summation 2%, ethyl hydroxybenzoate is 2 ‰ of above-mentioned effective technique adjuvant weight summation.
Embodiment 4, Radix Notoginseng 65, Rhizoma Paridis 35, Rhizoma Polygoni Cuspidati 35, Herba Houttuyniae 50, Radix Glycyrrhizae 20, and effective technique adjuvant: glyceryl monostearate 75, white vaseline 90, stearic acid 115, sodium laurylsulfate 12, glycerol 90, azone, ethyl hydroxybenzoate, wherein, azone be above-mentioned effective technique adjuvant weight summation 3%, ethyl hydroxybenzoate is 3 ‰ of above-mentioned effective technique adjuvant weight summation.
Embodiment 5, Radix Notoginseng 58, Rhizoma Paridis 28, Rhizoma Polygoni Cuspidati 28, Herba Houttuyniae 43, Radix Glycyrrhizae 12, and effective technique adjuvant: glyceryl monostearate 68, white vaseline 83, stearic acid 111, sodium laurylsulfate 9, glycerol 83, azone, ethyl hydroxybenzoate, wherein, azone be above-mentioned effective technique adjuvant weight summation 1.2%, ethyl hydroxybenzoate is 1.2 ‰ of above-mentioned effective technique adjuvant weight summation.
Embodiment 6, Radix Notoginseng 63, Rhizoma Paridis 33, Rhizoma Polygoni Cuspidati 33, Herba Houttuyniae 47, Radix Glycyrrhizae 17, and effective technique adjuvant: glyceryl monostearate 73, white vaseline 88, stearic acid 114, sodium laurylsulfate 11, glycerol 87, azone, ethyl hydroxybenzoate, wherein, azone be above-mentioned effective technique adjuvant weight summation 2.8%, ethyl hydroxybenzoate is 2.8 ‰ of above-mentioned effective technique adjuvant weight summation.
A kind of processing technology of the external application ointment for the treatment of children with tracheal-bronchitis, pneumonia, comprise in the step: (1) gets first Radix Notoginseng, Rhizoma Paridis dry powder, adopting percolation concentration is 65% ethanol percolate extraction, carry out in two steps, soaked 1-3 hour for the first time, isolate raw material adding ethanol and carry out the immersion second time, soaked 12-24 hour, after the separation, the alcohol extract alcohol extract is concentrated, and being concentrated into proportion is that 1.1-1.3 is for subsequent use; (2) get Rhizoma Polygoni Cuspidati, Herba Houttuyniae, Radix Glycyrrhizae, drying and crushing to 20 order fine powder, water decocts, the isolated by filtration medicinal liquid carries out in two steps, the first step decocts with water 1-1.5 hour, isolate medicinal residues and decoct with water again 40-60 minute, the filtering medicinal residues are concentrated into proportion after twice aqueous extract mixes and are 1.1-1.3, and are for subsequent use; (3) get vaseline, stearic acid, glyceryl monostearate, ethyl hydroxybenzoate, with aforementioned four material hot melts and stir to oil phase, for subsequent use; (4) get sodium laurylsulfate, glycerol, azone, add above-mentioned alcohol extract, water extract mixing, be heated to water, for subsequent use; (5) oil phase that step (3) is obtained is added to aqueous phase, stirs, and can make preparation after being cooled to room temperature; (6) pack, dispatch from the factory, when packing, pack every 10 gram with moulding pipe or aluminum pipe.In use, consumption: determine according to infant age size that generally general each with 1/2 bag below 5 years old, namely 5 grams got final product to be coated with very thin even one deck with 1 bag more than 10 years old at every turn with 2/3 bag in 5 years old ~ 10 years old at every turn; The coating scope: this ointment directly namely is equivalent to the horizontal line of third dorsal vertebra with the horizontal line that connects for omoplate hilllock, left and right sides mid point (1/2 place) in anterior axillary line, the infant left and right sides, lower on the skin of back between the twelfth rib bone horizontal line; Therapeutic Method and the course for the treatment of: with the skin of electromagnetic wave irradiation corresponding site 10 minutes, irradiation distance was moderate, get final product with warm, notes occuring the irradiation scald before coating; Shone 5 minutes with electromagnetic wave behind the coating, coating skin was worn the clothes with dried infant and was got final product this moment again.In family as without electromagnetic wave, also can at coating behind the available heat towel wiping skin rubefaction.
An adding that important feature is Rhizoma Polygoni Cuspidati of the present invention, with the monarch drug Radix Notoginseng, and the ministerial drug Rhizoma Paridis complement each other, can assist and strengthen improving pulmonary circulation and the effect of blood circulation promoting and blood stasis dispelling, relieving stagnation and freeing network vessels, anti-erythrocyte and antiplatelet aggregation being arranged of monarch drug Radix Notoginseng.The lung microcirculation is unobstructed, and blood plasma oozes out minimizing, has so just alleviated hypoxic-ischemic, alleviates pulmonary epithelial cells swelling and necrosis, and alveolar structure is early recovered.On the other hand, the microcirculatory improvement of lung also makes the macrophage phagocytic digestion power in the lung tissue strengthen, and also can secrete a large amount of interferon and natural killer cell NK cytoactive is strengthened with the deactivation cause of disease, removes as early as possible cause of disease, degeneration necrosis tissue and exudate become pneumonopathy and organize early reparation.
Another one important feature of the present invention is the dosage form of this external application ointment, owing to this external application ointment formulation is extracted, made behind the efficient concentration by effective ingredient, skin can very fast absorption behind the coating, absorb the means acceleration skin absorption that to seal hot skin with electromagnetic wave irradiation or pad towel in order to accelerate skin, obviously reducing behind the coating and with the gargalesthesia infant, only is＜1%.And traditional pneumonia plaster when making owing to do not pass through the extraction of the effective ingredient of medicine, be black plaster actually, skin can not very fast absorption behind its coating, the incidence rate of local skin erythra has reached more than 47% behind the coating.
The result in clinical application of external application ointment formulation of the present invention shows to have following advantage:
1, the pure external application of Chinese medicine Ointment in Treatment of external application infantile pneumonia, especially evident in efficacy to refractory pneumonias such as delay property, the cure rate for the treatment of in 6 days reaches 93%;
2, the external application ointment made of the present invention is nontoxic to human body, simple for use, and safe no pain in the therapeutic process;
3, the patient with slight symptoms can use separately, to the mycoplasma pneumonia of light disease pneumonia and the outer symptom of some apneumias, and oral antibiotic or antiviral agents, external application ointment of the present invention does not need venous transfusion to cure;
4, venous transfusion and external application ointment of the present invention can be combined for the patient with severe symptoms, but can greatly reduce the natural law of intravenous injection antibiotics, deeply be subjected to infant and family members' thereof popular welcome, be the Gospel of pneumonia, tracheitis and bronchitis infant.
For showing that external application ointment of the present invention is to children with tracheal-bronchitis, the therapeutic effect of pneumonia, reach internal clinic from being in hospital and select 72 routine cases, wherein, the case choice criteria was: with Hu Yamei in 2002, Jiang Zaifang chief editor " all good fortune hall practical paidonosologies " the 7th edition fixed bronchopneumonia diagnostic criteria is standard, through conventional passages through which vital energy circulates antiinflammatory and symptomatic treatment more than 10 days and even had not yet fully recovered in 2 ~ 3 weeks, still have clinically cough in various degree, the symptom such as expectoration or asthma, auscultation of lung has the rale that more or less, and be difficult for disappearing, the two lung point lamellars of x line chest film inspection, streak shade absorbs not exclusively and all without congenital heart disease, pulmonary tuberculosis, myocarditis, malnutrition, rickets, anemia, the respiratory system congenital diseases, immunodeficiency, the complication such as leukemia and tumor.Infant is divided into two groups at random.Test group 32 examples, male's 18 examples, women's 14 examples; Age 0-1 year 6 examples, 2 ~ 3 years old 20 example, 4 ~ 7 years old 6 example; Conventional vein antiinflammatory and 10 ~ 14 days symptomatic treatment time, 22 examples, 15 ~ 21 days 10 examples.Matched group 40 examples, male's 24 examples, women's 16 examples; Age 0-1 year 8 examples, 2 ~ 3 years old 28 example, 4 ~ 7 years old 4 example; Conventional vein antiinflammatory and 10 ~ 14 days symptomatic treatment time, 26 examples, 15 ~ 21 days 14 examples.
Therapeutic scheme:
Experimental group: 32 examples are inactive conventional vein antiinflammatory and symptomatic treatment all, makes external application ointment formulation treatment of the present invention with above-described embodiment 3.Matched group: 40 examples are inactive conventional vein antiinflammatory and symptomatic treatment all, and with traditional pneumonia plaster treatment, wherein drug dosage and test group are complementary, and drug of topical application every day once continues 12 hours at every turn, and 6 days was 1 course for the treatment of, treated altogether 6 days.
Curative effect judging standard:
Cure: treat the respiratory symptoms such as (6 days) cough 1 course for the treatment of, expectoration, dyspnea with rapid and short breath and disappear, the two pulmonary rales of chest auscultation disappear, and two pulmonary respiration sounds are normal, the two lung point lamellar shade complete obiterations of x line chest film inspection.
Effectively: treat the most of disappearance of the respiratory symptoms such as (6 days) cough 1 course for the treatment of, expectoration, dyspnea with rapid and short breath, the two pulmonary rales of chest auscultation disappear substantially, but respiratory murmur still increases slightly.The two lung point lamellar shades of x line chest film inspection disappear substantially, but still have the streak shade that more or less.
Invalid: treat and still have the respiratory symptoms such as cough, expectoration, dyspnea with rapid and short breath 1 course for the treatment of (6 days), the two lungs of chest auscultation or a side lung still have the rale that more or less, and the two lungs of x line rabat or a side lung still have the some lamellar shade that more or less.
Clinical test results is as shown in table 1:
| Group | Cure (routine number) | Effectively (routine number) | Invalid (routine number) |
| Experimental group | 30 | 1 | 1 |
| Matched group | 0 | 22 | 18 |
As can be seen from Table 1,32 children with bronchial pneumonia external application medicines of the present invention are done therapeutic test, one 6 days courses for the treatment of cure rate up to 93.75%, substantially effectively account for 3.13%, invalid accounts for 3.13%, total effective rate is up to 96.88%.
Claims (9)
1. processing technology that is used for the external application ointment of children with tracheal-bronchitis, pneumonia, it is characterized in that: this processing technology may further comprise the steps:
(1) will effectively treat component gets the raw materials ready according to following ratio of weight and number:
Radix Notoginseng 55-65 part,
Rhizoma Paridis 25-35 part,
Rhizoma Polygoni Cuspidati 25-35 part,
Herba Houttuyniae 40-50 part,
Radix Glycyrrhizae 10-20 part;
(2) above-mentioned each component is pulverized respectively, is sieved:
(3) Radix Notoginseng after will pulverizing, sieving, Rhizoma Paridis soak with ethanol, separation soaking liquid, concentrated that the liquid alcohol extract is for subsequent use;
(4) Rhizoma Polygoni Cuspidati after will pulverizing, sieving, Herba Houttuyniae, Radix Glycyrrhizae water decoct, and the isolated by filtration medicinal liquid, concentrated to obtain water extract stand-by;
(5) effective technique component is got the raw materials ready according to following ratio of weight and number:
Glyceryl monostearate 65-75 part,
White vaseline 80-90 part,
Stearic acid 110-115 part,
Sodium laurylsulfate 8-12 part,
Glycerol 80-90 part,
The 1-3% of the above weight summation of azone,
The 1-3 ‰ of the above weight summation of ethyl hydroxybenzoate,
(6) with above-mentioned vaseline, stearic acid, glyceryl monostearate, ethyl hydroxybenzoate mixing hot melt, and stir to oil phase, for subsequent use;
(7) sodium laurylsulfate, glycerol, azone are mixed, and add in the step (3) in the alcohol extract, with step (4) in water extract remix, be heated to water, for subsequent use;
(8) oil phase that step (6) is obtained is added to aqueous phase, stirs, and can make external application ointment after being cooled to room temperature;
(9) pack, dispatch from the factory.
2. the processing technology of a kind of external application ointment for children with tracheal-bronchitis, pneumonia according to claim 1, it is characterized in that: the Radix Notoginseng in the step (3), Rhizoma Paridis soak with ethanol, carry out in two steps, soaked 1-3 hour for the first time, isolate raw material adding ethanol and carry out the immersion second time, soaked 12-24 hour, and after the separation, concentrated alcohol extract for subsequent use.
3. the processing technology of a kind of external application ointment for children with tracheal-bronchitis, pneumonia according to claim 2, it is characterized in that: used concentration of alcohol is 60-70%.
4. the processing technology of a kind of external application ointment for children with tracheal-bronchitis, pneumonia according to claim 1, it is characterized in that: alcohol extract is concentrated in step (3), and being concentrated into proportion is that 1.1-1.3 is for subsequent use.
5. the processing technology of a kind of external application ointment for children with tracheal-bronchitis, pneumonia according to claim 1, it is characterized in that: the Rhizoma Polygoni Cuspidati after step will be pulverized in (4), sieve, Herba Houttuyniae, Radix Glycyrrhizae water decoct, the isolated by filtration medicinal liquid carries out in two steps, the first step decocts with water 1-1.5 hour, isolate medicinal residues and decoct with water again 40-60 minute, the filtering medicinal residues, concentrated after twice aqueous extract mixes.
6. the processing technology of a kind of external application ointment for children with tracheal-bronchitis, pneumonia according to claim 5 is characterized in that: concentratedly after said aqueous extract mixes finishes in concentration tank, the extracting solution proportion after concentrated reaches 1.1-1.3.
7. the processing technology of a kind of external application ointment for children with tracheal-bronchitis, pneumonia according to claim 1, it is characterized in that: the pulverizing described in the step (2), the operation of sieving are that Radix Notoginseng, Rhizoma Paridis, Rhizoma Polygoni Cuspidati, Herba Houttuyniae, Radix Glycyrrhizae powder are broken to the 18-22 order.
8. external application ointment that is used for children with tracheal-bronchitis, pneumonia treatment,, it is characterized in that: comprise in the components by weight percent of the raw material of Chinese medicine in this external application ointment than selecting materials, obtaining liquid active ingredients, mix mutually the medicine of formation with the oil phase adjuvant via extraction process according to prescription Chinese herbal medicine components by weight percent:
Radix Notoginseng 55-65 part,
Rhizoma Paridis 25-35 part,
Rhizoma Polygoni Cuspidati 25-35 part,
Herba Houttuyniae 40-50 part,
Radix Glycyrrhizae 10-20 part.
9. the external application ointment of said children with tracheal-bronchitis, pneumonia treatment according to claim 8 is characterized in that: comprise in the components by weight percent of the oil phase adjuvant in this external application ointment:
Glyceryl monostearate 65-75 part,
White vaseline 80-90 part,
Stearic acid 110-115 part,
Sodium laurylsulfate 8-12 part,
Glycerol 80-90 part,
The 1-3% of the above weight summation of azone,
The 1-3 ‰ of the above weight summation of ethyl hydroxybenzoate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210584353.1A CN103071020B (en) | 2012-12-30 | 2012-12-30 | Externally applied ointment for treating child trachitis-bronchitis and pneumonia, and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210584353.1A CN103071020B (en) | 2012-12-30 | 2012-12-30 | Externally applied ointment for treating child trachitis-bronchitis and pneumonia, and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103071020A true CN103071020A (en) | 2013-05-01 |
| CN103071020B CN103071020B (en) | 2014-08-20 |
Family
ID=48147865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210584353.1A Active CN103071020B (en) | 2012-12-30 | 2012-12-30 | Externally applied ointment for treating child trachitis-bronchitis and pneumonia, and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103071020B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180353459A1 (en) * | 2012-06-05 | 2018-12-13 | Olatec Therapeutics Llc | Pharmaceutical composition for treating inflammation and pain |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1299651A (en) * | 2000-02-03 | 2001-06-20 | 天津中医学院第二附属医院 | Dressing for treating infantile bronchitis and pulmonitis and its preparation |
| CN1451433A (en) * | 2003-05-07 | 2003-10-29 | 赤峰万泽制药有限责任公司 | Shenji ointment and preparing process thereof |
| CN1631369A (en) * | 2003-12-23 | 2005-06-29 | 高克 | Cream for treating skin disease |
| CN101507798A (en) * | 2009-03-24 | 2009-08-19 | 宋英杰 | Traditional Chinese medicine capable of chronic bronchitis and pulmonary heart disease |
-
2012
- 2012-12-30 CN CN201210584353.1A patent/CN103071020B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1299651A (en) * | 2000-02-03 | 2001-06-20 | 天津中医学院第二附属医院 | Dressing for treating infantile bronchitis and pulmonitis and its preparation |
| CN1451433A (en) * | 2003-05-07 | 2003-10-29 | 赤峰万泽制药有限责任公司 | Shenji ointment and preparing process thereof |
| CN1631369A (en) * | 2003-12-23 | 2005-06-29 | 高克 | Cream for treating skin disease |
| CN101507798A (en) * | 2009-03-24 | 2009-08-19 | 宋英杰 | Traditional Chinese medicine capable of chronic bronchitis and pulmonary heart disease |
Non-Patent Citations (1)
| Title |
|---|
| 张淑芬等: "抗白灵霜治疗局限型白癜风31例", 《南京中医药大学学报》, vol. 13, no. 3, 31 December 1997 (1997-12-31) * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180353459A1 (en) * | 2012-06-05 | 2018-12-13 | Olatec Therapeutics Llc | Pharmaceutical composition for treating inflammation and pain |
| US10751316B2 (en) * | 2012-06-05 | 2020-08-25 | Olatec Therapeutics Llc | Pharmaceutical composition for treating inflammation and pain |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103071020B (en) | 2014-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104174006A (en) | Chinese medicinal navel patch used for treating infantile diarrhea and preparation method thereof | |
| CN107308419A (en) | A kind of Traditional Chinese medicine for steeping foot powder for treating stomach cold crymodynia | |
| CN102552361A (en) | Externally applied medicinal liquor and preparation method thereof | |
| CN103071020B (en) | Externally applied ointment for treating child trachitis-bronchitis and pneumonia, and preparation method thereof | |
| CN104784245A (en) | Medicine for treating cervical cancer | |
| CN108355042A (en) | A kind of anti-inflammatory analgetic ointment and preparation method thereof | |
| CN104645082B (en) | A kind of capsule for treating hepatitis and preparation method thereof | |
| CN103656048A (en) | Drug for treating cow mastitis and preparation method thereof | |
| CN103394042A (en) | Traditional Chinese medicine tincture used for adjuvant therapy on bone fracture | |
| CN112675280A (en) | Composition for preventing and treating carsickness and preparation method thereof | |
| CN107335034A (en) | A kind of external medicine composition for treating leucoderma and its application | |
| CN106729011A (en) | A kind of topical composition | |
| CN101721610B (en) | Medicine for treating tumors | |
| CN106728618A (en) | A kind of Chinese medicine for treating Severe Acute Pancreatitis SAP | |
| CN105963529A (en) | Medicinal liquor for curing scabies and preparation method thereof | |
| CN105267939A (en) | Traditional Chinese medicine composition for treating superficial phlebitis | |
| CN105106712A (en) | Nutritional porridge capable of helping postoperative recovery of cancer patient and preparation method thereof | |
| CN112245551A (en) | Pure traditional Chinese medicine transdermal liniment for treating liver diseases and preparation method thereof | |
| CN105031389A (en) | Traditional Chinese medicine tablet for restraining malignant tumor breeding in cooperation with radiotherapy and preparing method of traditional Chinese medicine tablet | |
| CN104435525A (en) | Traditional Chinese medicine composition for preventing and treating bacterial endocarditis and preparation method of traditional Chinese medicine composition | |
| CN104840793A (en) | Pure traditional Chinese medicine cooling gel sheet for high fever of kids and method for preparing same | |
| CN111494557A (en) | Plant enzyme traditional Chinese medicine wine and preparation method thereof | |
| CN115381913A (en) | Formula and preparation method of hemorrhoid patch | |
| CN104189195B (en) | The Traditional Chinese medicine medicated bath for the treatment of neurotic skin pruritus and preparation method | |
| CN114010755A (en) | Preparation for controlling uric acid and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |